Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2005-1-12
pubmed:abstractText
Dose-reduced allogeneic peripheral blood stem cell transplantation (PBSCT) is a therapeutic approach for patients with haematological malignancies who are not eligible for conventional allogeneic PBSCT. We analysed early development of lymphocyte subpopulations and the occurrence of cytomegalovirus (CMV) reactivation and acute graft-versus-host reaction (GvHD) in patients undergoing the protocol according to Slavin vs conventionally treated patients. Lymphocyte status prior to conditioning and at day +30 after allogeneic PBSCT was determined in 24 out of 51 patients who received conventional allogeneic PBSCT (eg cyclophosphamide plus total body irradiation) and compared with 27 patients being treated according to the Slavin protocol (fludarabine, busulphan and ATG). There is a significant delay in CD4 (T helper) cell development and consecutive lower CD4/CD8 ratios and a better reconstitution of CD8 (T cytotoxic) and NK (natural killer) cells after the Slavin protocol. Patients undergoing this protocol and no, or only grade I, acute GvHD show an even better NK cell reconstitution compared to patients with grade II-IV GvHD. A low CD4/CD8 ratio represents a CMV risk factor only in conventionally treated patients with grade 0-I GvHD, while after preparative regimen according to the Slavin protocol, the NK/CD8 ratio might be a marker for the prediction of CMV reactivation in addition to CMV risk status.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0268-3369
pubmed:author
pubmed:issnType
Print
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
183-90
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15531897-Adult, pubmed-meshheading:15531897-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15531897-Combined Modality Therapy, pubmed-meshheading:15531897-Cytomegalovirus Infections, pubmed-meshheading:15531897-Female, pubmed-meshheading:15531897-Graft Survival, pubmed-meshheading:15531897-Graft vs Host Disease, pubmed-meshheading:15531897-Hematologic Neoplasms, pubmed-meshheading:15531897-Humans, pubmed-meshheading:15531897-Killer Cells, Natural, pubmed-meshheading:15531897-Lymphocyte Count, pubmed-meshheading:15531897-Male, pubmed-meshheading:15531897-Middle Aged, pubmed-meshheading:15531897-Peripheral Blood Stem Cell Transplantation, pubmed-meshheading:15531897-Prognosis, pubmed-meshheading:15531897-Retrospective Studies, pubmed-meshheading:15531897-Transplantation, Homologous, pubmed-meshheading:15531897-Transplantation Conditioning, pubmed-meshheading:15531897-Virus Activation
pubmed:year
2005
pubmed:articleTitle
Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT.
pubmed:affiliation
Mildred Scheel Station für Knochenmarktransplantation, Department of Internal Medicine II, Medical Faculty, Friedrich Schiller University, Erlanger Allee 101, Jena 07740, Germany. sebastian.scholl@med.uni-jena.de
pubmed:publicationType
Journal Article, Comparative Study